Allergan Snubs Valeant's Olive Branch, Hints At Other Deal
Allergan Inc. on Thursday swatted down requests to meet Valeant Pharmaceuticals International Inc. at the bargaining table to discuss the company's hostile $53 billion bid, and gave its strongest public indication...To view the full article, register now.
Already a subscriber? Click here to view full article